Featured Story | By Zoey Becker Biogen is trying to escape the dark cloud that controversial drug Aduhelm brought in. In a recent SEC filing, the company wrote off $233 million of the drug's inventory. read more |
| |
|---|
|
Top Stories By Andrea Park Hanger agreed to be acquired by Patient Square Capital, a Silicon Valley healthcare investment firm that just last month joined in on the $890 million acquisition of biopharmaceutical developer Radius Health and, a month earlier, launched its own $300 million therapeutics-focused startup incubator. read more By Annalee Armstrong Will any of the three leading Alzheimer's disease therapies make it through their upcoming readouts? Executives from Biogen and Roche seem to be tempering expectations in second-quarter earnings updates. Lilly is the next to report. read more By Robert King Tenet Healthcare posted a $38 million profit for the second quarter of the year due in part to a debilitating cyberattack but contract labor costs started to moderate. read more By Ben Adams Roche is hyping up the early financials coming in for its eye disease therapy Vabysmo as the Swiss major looks to take on the might of Regeneron and Bayer’s major blockbuster, Eylea. Despite only being approved at the start of the year and the launch coming several months later, Roche saw Q2 sales hit a healthy CHF 109 million ($112 million). read more By Andrea Park The nerve repair process just got a lot simpler, thanks to a new FDA 510(k) clearance for a device that essentially amounts to a piece of Scotch tape that can quickly and effectively rejoin nerve ends. read more By Paige Minemyer The survey highlights the need for both payers and providers to find ways to address the friction in the care experience for patients, and make it easier for them to access care in a convenient way. These digital options for care navigation are likely to be a critical tool in the arsenal for both payers and providers in thinking about ways to improve member retention. read more By Gabrielle Masson After talks with the FDA, Vertex Pharmaceuticals has been given the go ahead to advance its non-opioid pain killer into phase 3 trials, which are set to begin in the last quarter of this year. read more By Conor Hale ForSight Robotics aims to bring the benefits of a steady, remote-controlled hand to cataract eye surgery, and now the Israeli startup is $55 million closer to its goal. The company previously raised $10 million in a seed funding round last year to advance its Oryom microsurgery system. read more By Fraiser Kansteiner After a sales peak in 2022, Paxlovid revenues are due to decrease from 2023 onward, thanks to a second round of booster vaccines and predications of fewer cases that require hospitalization, data and analytics outfit GlobalData predicts. read more By Heather Landi Capsule joins the growing list of digital health and health tech companies slashing head counts in the face of a market downturn. read more By Max Bayer The second half of 2022 was always going to be a high-stakes moment for VistaGen Therapeutics as it awaited data from two phase 3 trials for a social anxiety disorder nasal spray. And the stakes just got even higher, after the results of the first of the two found that the company swung and missed. read more By Ben Adams Should pharma reps keep wheeling their cases into doctors' offices? Maybe not. Video meetings are three times more effective than in-person interactions when it comes to driving new prescriptions, a new study found. read more By Natalie Missakian Biohaven is hammering home the “all in one” simplicity of Nurtec ODT to treat and prevent migraine in a new campaign that brings back reality star, influencer and entrepreneur Khloe Kardashian as celebrity spokeswoman. read more Resources Sponsored by: NetApp Could cloud be the cure for your EHR headaches? See our infographic on how moving to the cloud can slash financial and administrative burdens. Sponsored by: Cognizant Explore how Cognizant SIP helped Roche streamline its global feasibility process. Sponsored by: Blue Matter Consulting This e-book covers the 12 most common pitfalls for companies entering European markets for the first time, offering guidance to help growing companies avoid them and succeed. Sponsored by: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Thermo Fisher Scientific The journey for starting or expanding a lab can be exhilarating, while also being challenging--learn how this free program provides savings and solutions to support your goals. Sponsored by: Catalent Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent Carla Vozone discusses the significant trends in the OINDP segment including large molecules and novel indications, changes within CDMOs and various challenges facing the industry. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. | 
